Skin Care Medicine

Approx. Rs 9,000 / TubeGet Latest Price

Opzelura (ruxolitinib 1.5%) cream is a topical selective Janus kinase (JAK) inhibitor approved by the FDA for the short-term and non-continuous treatment of mild to moderate atopic dermatitis in non-immunocompromised (patients without weakened immune systems) adult and pediatric patients 12 years of age and older who disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

Mild to moderate atopic dermatitis is generally determined by skin involvement (how much of your body surface is affected) and severity of symptoms such as itch and rash.  It's important to talk to your doctor about how atopic dermatitis affects not just your skin but also other aspects of your life. 

Together, you and your healthcare provider can determine if Opzelura is an appropriate treatment option.  

View Complete Details